Guest guest Posted September 8, 2010 Report Share Posted September 8, 2010 Keeping you informed. This letter was published last month after the story broke about the website not containing the risks of using Gleevec. This is to set the record straight and the website has now been shut down. August, 2010 Dear Patient or Caregiver: Recently Novartis Pharmaceuticals Corporation received a Warning Letter from the US Food and Drug Administration (FDA) stating that our www.cmlalliance.com website contained misleading information about Gleevec because the website did not contain any information about the serious risks of using Gleevec. As someone registered to receive information from the program, this letter is being sent to you at FDA’s request to provide important information about these serious risks and to correct the messages and presentations that you may have seen on this website about Gleevec that the FDA considered to be misleading. Novartis takes the FDA Warning Letter very seriously and as a result has suspended this website and all related materials. Novartis values the safety of patients and believes that providing patients access to accurate, timely and relevant disease information on rare diseases is important. The entire letter can be read at this website: http://www.cmlalliance.com/Aug-2010-Novartis-FDA-Ltr2CMLRev7.pdf FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.